A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Primary Vitreoretinal Lymphoma

In brief

A prospective, randomized, double-masked, dosing-frequency-controlled, multicenter clinical trial evaluating the safety and activity of intravitreally injected ADX-2191 (methotrexate injection USP) in patients with primary vitreoretinal lymphoma

Key facts

Study ID

NCT07402876

Run by

Aldeyra Therapeutics, Inc.

People needed

20

Starts

2026-02-01

Expected to finish

2026-12-01

Last updated by the study team

2026-02-11

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 21 years old or older; of any gender
• Biopsy proven primary vitreoretinal lymphoma
• Presence of lymphomatous vitreous cells at the Screening Visit and/or any eye that has been vitrectomized to confirm the diagnosis of primary vitreoretinal lymphoma
• Willingness to participate in the clinical trial as evidenced by signing of an informed consent

You may not qualify if…

• Known allergy or hypersensitivity to methotrexate
• Planned eye surgery during the clinical trial
• Women of childbearing potential who are pregnant or lactating
• Pre-existing ocular or non-ocular conditions or diseases that, in the opinion of the investigator, could interfere with the conduct or interpretation of the clinical trial
• Use of systemic methotrexate within one week prior to treatment

Where it is running

• Bascom Palmer Eye Institute — Miami, Florida, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.